Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects

Next Previous
Search
Trial Profile

A Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SCY-247 (Primary)
  • Indications Aspergillosis; Candidiasis; Zygomycosis
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Mar 2025 According to SCYNEXIS, Inc. media release, results from this study is expected in Q3 of 2025 and look forward to completion of the trial later this year.
    • 18 Dec 2024 According to SCYNEXIS, Inc. media release, the company announced that it has completed the dosing of the first cohort of subjects in its Phase 1 trial of SCY-247.
    • 18 Dec 2024 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top